This Viewpoint defines an AI agent as a feedback-driven system that maintains task state, selects among governed tools, observes results, and revises its plan under explicit safety constraints, and separates agents from multimodal foundation models, retrieval-augmented generation, and fixed workflow automation.
Abstract
Cancer diagnosis depends on data from radiology, digital pathology, molecular profiling, laboratory testing, and longitudinal clinical records. AI performs well in selected tasks, but most systems remain narrow and disconnected from the iterative reasoning required in oncology. This Viewpoint defines an AI agent as a feedback-driven system that maintains task state, selects among governed tools, observes results, and revises its plan under explicit safety constraints. This definition separates agents from multimodal foundation models, retrieval-augmented generation, and fixed workflow automation. We organize the discussion across multimodal data collection, preprocessing, fusion and representation learning, and diagnostic decision support. We distinguished agent-level evidence, component- or infrastructure-level evidence, and prospective propositions throughout. Clinical translation will require resilient failure handling, guideline version control, prospective evaluation, computational and workflow feasibility, and clinician authority over final decisions. The near-term opportunity is therefore transparent and traceable clinical decision support rather than autonomous cancer diagnosis.
Medical imaging serves as a critical source of evidence for cancer diagnosis, treatment, and follow-up. However, most existing medical imaging artificial intelligence (AI) systems still operate on predefined tasks and inputs, limiting their ability to address the evolving needs of clinical practice and research. AI age...
Rui Yao· Chinese journal of cancer re...· 0 citations
Neuro-oncology decisions require coordinated interpretation of serial MRI, pathology, molecular markers, treatment history, performance status, and evolving guidelines. We present TumorBoard, a multi-agent decision-support system built around a shared longitudinal case state and an auditable claim-evidence ledger. Spec...
Yantong Liu, Zhe-Yu Zhang, Run-Peng Liu et al.· 0 citations
The promise of AI-enabled multimodal precision medicine lies not in combining every available data stream, but in determining which molecular, morphological, and clinical information is necessary, complementary, and actionable for an individual patient at a specific decision point.
Rong Wei, Qi-Ping Zheng· American Journal of Clinical...· 0 citations
Current evidence is insufficient to establish improvements in MDT decision quality or patient outcomes, and AI should be regarded as a supervised support tool rather than a replacement for expert multidisciplinary judgment.
A. Nikitaras, S. M. Tsoti, M. Pramateftakis· Frontiers in Oncology· 0 citations
LUCAID is an agentic AI system for precision lung cancer pathology that combines diagnostic reasoning with nine modules that cover the full routine workflow, from quality control, tumor detection and segmentation, histological subtyping, tumor microenvironment profiling, tumor cellularity quantification, and predictive...
M. Eich, K. Standvoss, Timo Milbich et al.· 0 citations
Recent advances and emerging translational evidence for clinically oriented MML in glioblastoma is summarized, with particular emphasis on MRI-centered systems that integrate imaging with pathology, selected molecular measurements, and longitudinal clinical context.
Amin Zadeh-Shirazi, Bryan W. Day, Hui K. Gan et al.· Frontiers in Oncology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.